Mangoceuticals, Inc.
MGRX Nasdaq
SEC CIK 1938046
Follow Mangoceuticals
Weekly email: filings, results
Revenue, last quarter
$69.5K
−17.5% vs same quarter last year
Net income
−$3.6M
+53.4% vs same quarter last year
EPS, diluted
−$0.19
+72.5% vs same quarter last year
Operating cash flow
−$1.1M
+7.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $456K | −$20.6M |
| FY24 | $615.9K | −$8.7M |
| FY23 | $731.5K | −$9.2M |
| FY22 | $8.9K | −$2M |
| FY21 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 54.9% | −3954.3% | −4526.8% |
| FY24 | 61.7% | −1294.4% | −1413.6% |
| FY23 | 59% | −1260.3% | −1259.4% |
| FY22 | 54.3% | −22279.7% | −22352.1% |
| FY21 | - | - | - |
- Mangoceuticals
- Healthcare median
Show the numbers
| Year | Mangoceuticals | Healthcare median |
|---|---|---|
| FY25 | −4526.8% | −30.6% |
| FY24 | −1413.6% | −47% |
| FY23 | −1259.4% | −58% |
| FY22 | −22352.1% | −80.4% |
| FY21 | - | −71.9% |